Title: GW501516 in subjects with low HDL-cholesterol (Phase II, GlaxoSmithKline)
A multicenter, randomized, double‑blind, placebo‑controlled dose-range study (12 weeks) investigating 2.5, 5.0, and 10 mg daily in adults with HDL‑C ≤45 mg/dL.
Results: up to 17% increase in HDL‑C, 7–15% reduction in LDL and triglycerides, improved lipoprotein subclass profiles (e.g., fewer small LDL, increased HDL particles) Clinical Trials Register+10BEHEMOTH LABZ+10Therapeutic Goods Administration (TGA)+10Wikipedia+7PubMed+7ClinConnect+7.
Title: Lipoprotein subclass profiling with GW501516
A small exploratory arm (n≈37) escalated from 5 mg to 10 mg daily.
Findings: significant reductions in very‑LDL (~19%), intermediate LDL (~52%), small LDL (~14%), and increases in HDL particle number (~10%) PubMed.
Title: Safety and tolerability of daily GW501516 dosing in healthy volunteers
Phase I/II trials (2000–2007) assessed 2.5–10 mg once daily for up to 12 weeks in sedentary adults.
No significant adverse impact on liver or muscle enzymes. Triglycerides improved, and HDL rose modestly, with no acute safety signals noted Reddit.
Title: Effects of GW501516 on endurance, metabolism, and cancer risk
In mice and obese non‑human primates, Cardarine significantly enhanced endurance performance, fatty acid oxidation, and HDL elevation; but long-term studies revealed carcinogenicity in multiple organs, prompting drug development termination in 2007 Reddit+10Wikipedia+10biolongevitysupplements.com+10.
Animal models established changes in gene expression associated with mitochondrial biogenesis, anti-inflammatory cytokines, and energy metabolism via PPARδ activation biolongevitysupplements.com.
Originally developed for treating metabolic syndrome, obesity, dyslipidemia, and cardiovascular conditions—clinical development reached Phase II but was terminated due to long-term carcinogenicity in animals Clinical Trials RegisterPubMedHealth+1Reddit+1Wikipedia+1PubMed+1CDEK+1MedPath+1PubMed+7The Conversation+7BEHEMOTH LABZ+7BEHEMOTH LABZ+3The New Yorker+3Therapeutic Goods Administration (TGA)+3.
Mechanism: Selective PPARδ agonist that enhances fatty acid oxidation, HDL production, and mitochondrial function via transcriptional activation in skeletal muscle and liver tissues Wikipedia+10Reddit+10biolongevitysupplements.com+10.
Safety concerns: Chronic rodent exposure at high doses caused tumors in multiple tissues, including liver, bladder, stomach; human trials showed no acute signals, but were short-term and did not assess carcinogenicity risks WikipediaThe Conversationbiolongevitysupplements.com.
Regulatory status: Not FDA approved. Added to WADA’s prohibited list in 2009 due to misuse in sports and health risks Wikipedia+1biolongevitysupplements.com+1.
Original price was: $75.00.$60.00Current price is: $60.00.
46 in stock
Provided by Combat Research – Research-Grade Chemicals
CAS Number: 317318-70-0
Other Names: GW-501516, Endurobol
IUPAC Name:
2-[2-methyl-4-({[4-(trifluoromethyl)phenyl]methyl}thio)phenyl]-2-ethylpropan-1-oic acid
Molecular Formula: C₂₁H₁₈F₃NO₃S
Molecular Weight: 453.50 g/mol
Cardarine (GW-501516) is a selective PPARδ (peroxisome proliferator-activated receptor delta) agonist developed for its potential to enhance endurance, regulate lipid metabolism, and influence energy utilization. At Combat Research, we supply 10mg dry fill powder capsules for Research Use Only (RUO). Each capsule is precision-filled to ensure uniformity, purity, and consistent results in experimental settings.
This formulation supports research focused on:
Endurance and energy metabolism regulation
Mitochondrial efficiency and fatty acid oxidation
Lipid profile modulation under high-stress or caloric restriction
Performance studies in tactical or environmental stress models
Form: Dry Fill Powder Capsules
Concentration: 10 mg per capsule
Appearance: Off-white to beige powder in clear or opaque gelatin capsule
Purity: ≥98% (HPLC Verified)
Grade: Research Use Only (RUO)
All capsules are securely packaged in tamper-evident containers and produced under controlled lab conditions to ensure compound integrity and traceability.
This compound is provided exclusively for non-clinical research, including:
Academic and government-funded lipid metabolism research
Tactical and military performance studies
Preclinical studies exploring PPARδ modulation
Cited in various preclinical studies, some of which are available on PubMed, NIH.gov, and ClinicalTrials.gov.
NOT approved by the FDA for use in humans or animals
Classified as Research Use Only under 21 CFR 312.2(b)
Not for diagnostic, therapeutic, or clinical applications
Distributed exclusively to research professionals and qualified institutions
Disclaimer: Cardarine (GW-501516) provided by Combat Research is intended strictly for laboratory research use only. It is not a dietary supplement, drug, or approved treatment, and not for human or veterinary use. Any off-label or unauthorized application is strictly prohibited and may violate federal laws. All customers must be trained professionals or institutional representatives who understand and comply with relevant research regulations.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.